Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for choroidal neovascular membranes in high myopia
2007-006785-15Phase 4Active
- Sponsor
- IOBA
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of bevacizumab in Subretinal neovascularization and myopic maculopathy (MM), sponsored by IOBA. Primary endpoint: Best corrected visual acuity improvement. Started Jan 2008; status: active.
02
Drugs
bevacizumab
03
Conditions
Subretinal neovascularizationmyopic maculopathy (MM)
Beyond the preview
Go deeper on 2007-006785-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006785-15.